Company profile
Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ: COAG · Healthcare · Biotechnology
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 39
v0.1 · 5/100 weight · pillars only
↑ market scale, workforce scale · ↓ listing tenure, filing timeliness
Methodology →Revenue TTM
—
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
—
Employees
59
as of 2026-08-02
Market cap
$95.5M
as of 2026-08-02
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
No filed financials — private or non-XBRL filer.
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Hemab Therapeutics Holdings, Inc. Common Stock’s financial profile?
Hemab Therapeutics Holdings, Inc. Common Stock has no structured financials on file — private or non-XBRL filer.
Peers · Healthcare
enGene Holdings Inc.——Biomea Fusion, Inc.——Park Dental Partners, Inc. Common Stock——Cognition Therapeutics, Inc.——Acrivon Therapeutics, Inc. Common Stock——NDT Pharmaceuticals Inc.——Neighbors
Middlesex →Key facts
CEOBenny Sorensen
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: COAG
Employees59
IPO date2026-05-01
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.